3rd World Congress of Cutaneous Lymphomas
October 26-28, 2016
Alfred Lerner Hall
COLUMBIA UNIVERSITY

Chairs: Maarten Vermeer, MD, PhD & Larisa Geskin, MD
Register at www.columbiacme.org
WEDNESDAY, October 26, 2016

07:00-08:30  EORTC CLTF Board Meeting
08:30-08:45  Welcome Remarks  Martin Vermeer & Larisa Geskin
08:45-10:10  Scientific Session A. Classification & Clinical Pathology

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

- **Cutaneous Lymphomas & the 2016 WHO Classification**
  - Studies in folliculotropc MF and transformed MF: consequences for the ISCL/EORTC staging system  
    - Steven Swerdlow  20
  - Primary Cutaneous Aggressive Epidermotropic T-Cell Lymphomas: reappraisal of a provisional entity in the 2016 WHO classification of Lymphomas  
    - Joan Guitart  9
  - Primary Cutaneous CD8-Positive Aggressive Epidermotropic Cytotoxic T-Cell Lymphoma: Clinico-Pathological Features and Genomic Alterations  
    - Emilio Berti  9
  - CD8+ mycosis fungoides: an indolent lymphoproliferative disorder  
    - Estela Martinez-Escala  9
  - Unilesional mycosis fungoides is associated with increased expression of miR-17-92, Th1 cytokine profile and absence of Th2  
    - Lilach Moyal  9
  - Pediatric mycosis fungoides: Clinico-pathologic characteristics and outcome and a study of the human leukocyte antigen system  
    - Emmilia Hodak  9

10:10-10:30  Break & Poster Viewing
10:30-12:00  Scientific Session B. Pathogenesis & Apoptosis

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

- **Introduction + Apoptotic Abnormalities in CTCL: Pathogenetic and Therapeutic Implications**  
  - Gary Wood  15
- **Micro RNA regulatory circuits in chemotherapy-induced apoptosis in CTCL cells**  
  - Robert Gniadecki  9
- **Evidence for Phospholipase C Gamma 1 (PLCG1) mutations augmenting aberrant T-cell Receptor signalling in Sézary Syndrome**  
  - Varsha M. Patel  9
- **A comparison of transcriptome sequencing and TOX chromatin immunoprecipitation data identifies putative downstream effects of transcription factor dysregulation in Sézary syndrome**  
  - Brittany O. Dulmage  9
- **Inactivation of runx3/p46 Promotes Cutaneous T-Cell Lymphoma**  
  - Chalid Assaf  9
- **STAT3 activation results from the epigenetic abrogation of miR-124 in Cutaneous T-cell lymphoma**  
  - Fernando Gallardo  9
- **Novel high-throughput virome capture sequencing technique failed to identify viral pathogens in patients with cutaneous T-cell lymphoma**  
  - Mary E. Anderson  9
- **Mitochondrial retrograde signaling regulates sensitivity to metabolic stress and allows selective targeting of cutaneous T-cell lymphoma**  
  - Stefan M. Schieke  9

12:00-13:00  Lunch & Poster Viewing
13:00-14:00  Scientific Session C. Multinational Collaborative Studies

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

- **Introduction**  
  - Youn H. Kim  5
- **Cutaneous Lymphoma International Consortium: An Advanced Stage Prospective Study Uniting International Expert Centres to Evaluate and Validate the Prognostic Index Model**  
  - Julia Scarisbrick  8
- **PROspective Cutaneous Lymphoma International Study (PROCLIPi) in Early Stage Mycosis Fungoides**  
  - Julia Scarisbrick  8
- **Global Patterns of Care in Advanced Stage Mycosis Fungoides/Sézary Syndrome: A Multicenter Retrospective Follow-up Study from the Cutaneous Lymphoma International Consortium**  
  - Pietro Quaglino  12
- **Validation of Central Pathology Review in Advanced-Stage Cutaneous T-cell Lymphomas, a Multi-Institutional and International Pathology Pilot Study**  
  - Alejandro Ariel Gru  10
- **USCLC update**  
  - Elise Olsen  10

14:00-15:00  Scientific Session D. Epidemiology & Population Studies

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

- **Introduction**  
  - Martin Weinstock  10
- **Introduction**  
  - Steven Stellman  15
- **The Incidence of Cutaneous T-Cell Lymphoma in The Veteran Population**  
  - Christina Del Guzzo  9
- **Relative frequency, clinical features, and survival outcomes of 395 patients with cutaneous lymphoma in Korea: a subgroup analysis per 10-year period**  
  - Woo Jin Lee  9
- **Characterization of 794 cutaneous lymphoma patients from a single center in Brazil**  
  - Denis Miyashiro  9
- **Cutaneous T-cell Lymphoma in Saudi population**  
  - Yousef Binamer  9
**Scientific Session E. Immunology & Immunopathogenesis**

**Chairs:** Sugaya, Querfeld, O'Malley, Rook

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Title</th>
<th>Author</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:00-15:20</td>
<td>Break &amp; Poster Viewing</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:20-17:00</td>
<td>Scientific Session E. Immunology &amp; Immunopathogenesis</td>
<td>The immune checkpoint receptors ICOS and PD1 in mycosis fungoides and Sézary syndrome: correlation with disease and outcome.</td>
<td>Christiane Querfeld</td>
<td>9</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Lack of support for a Th2 origin of Mycosis fungoides revealed by RNA sequencing</td>
<td>A.N. Bastidas-Torres</td>
<td>9</td>
</tr>
<tr>
<td></td>
<td></td>
<td>IL-10 is a biomarker of advanced mycosis fungoides and is required for maximal tumor formation in a murine model of CTCL</td>
<td>Xuesong Wu</td>
<td>9</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Interleukin-13 is over-expressed in cutaneous T-cell lymphoma cells and regulates their proliferation</td>
<td>Patrizia Fushiotti</td>
<td>9</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Dysfunctional cytokines production induced by Toll-like receptors activation in the Sézary syndrome</td>
<td>Kelly C. Gomes Manfrere</td>
<td>9</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TIGIT and Helios are Highly Expressed on CD4 T-Cells in Sezary Syndrome</td>
<td>Neha Jariwala</td>
<td>9</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Mycosis fungoides: new issues from microenvironment</td>
<td>Alessandro Pileri</td>
<td>9</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Impaired Secretion of CXCL9/MIG and CXCL10/IP-10 in Sezary Syndrome</td>
<td>Marina Torrealba</td>
<td>9</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Ineffective antibody-dependent cellular cytotoxicity in patients with late stage cutaneous T cell lymphoma</td>
<td>Emmanuella Guenova</td>
<td>9</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Characterization of the tumor microenvironment in primary cutaneous CD30-positive lymphoproliferative disorders: a predominance of CD163-positive M2 macrophages</td>
<td>Werner Kempf</td>
<td>9</td>
</tr>
<tr>
<td>17:30-19:30</td>
<td>Picture Taking &amp; Welcome Reception</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### THURSDAY, October 27, 2016

**ISCL Board of Directors Meeting**

**Scientific Session F. Biomarkers**

**Chairs:** Stadler, Iwatsuki, Geskin, Bagot

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Presenter</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>F-01</td>
<td>Increased Soluble CD226 in Sera of Patients with Cutaneous T-Cell Lymphoma Mediating Cytotoxic Activity against Tumor Cells via CD155</td>
<td>Naomi Takahashi</td>
<td>08:00-09:30</td>
</tr>
<tr>
<td>F-02</td>
<td>Evaluation of validated DNA methylation biomarkers in early Sézary syndrome patients</td>
<td>Wim Zoutman</td>
<td>08:00-09:30</td>
</tr>
<tr>
<td>F-03</td>
<td>Variability in CD30 and other biomarkers in Mycosis Fungoides/Sézary Syndrome (MF/SS): Challenges in Tissue Biomarker Interpretation</td>
<td>Ziba Rahbar</td>
<td>08:00-09:30</td>
</tr>
<tr>
<td>F-04</td>
<td>CXCL13 and BOB1 expression in initial biopsies of mycosis fungoides with stable early stage and later tumor stage disease</td>
<td>Ulrike Wehkamp</td>
<td>08:00-09:30</td>
</tr>
<tr>
<td>F-05</td>
<td>Usefulness of KIR3DL2 to diagnose, follow-up and manage the treatment of Sézary syndrome patients</td>
<td>Charlotte Hurabielle</td>
<td>08:00-09:30</td>
</tr>
<tr>
<td>F-06</td>
<td>c-MET is overexpressed in cutaneous T-cell lymphoma and represents a potential therapeutic target</td>
<td>Chalid Assaf</td>
<td>08:00-09:30</td>
</tr>
<tr>
<td>F-07</td>
<td>Biological and clinical significance of tryptophan catalyzing enzymes in patients with cutaneous T-cell lymphoma</td>
<td>Liisa Väkevä</td>
<td>08:00-09:30</td>
</tr>
<tr>
<td>F-08</td>
<td>Cell adhesion molecule 1 is a biomarker for leukemic cells in progressive or refractory Sézary syndrome</td>
<td>Keiji Iwatsuki</td>
<td>08:00-09:30</td>
</tr>
<tr>
<td>F-09</td>
<td>A reactivation signal, BZLF-1, is a biomarker for severe phenotypes of cutaneous EBV-associated T/NK lymphoproliferative disorders</td>
<td>Keiji Iwatsuki</td>
<td>08:00-09:30</td>
</tr>
</tbody>
</table>

**Scientific Session G. Genetics**

**Chairs:** Girardi, Whittaker, Ortiz Romero, Palomero

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Presenter</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>G-01</td>
<td>Validation and functional interrogation of JAK and STAT variants in Primary Cutaneous T-cell Lymphoma (CTCL)</td>
<td>Rosie M. Butler</td>
<td>10:35-12:00</td>
</tr>
<tr>
<td>G-02</td>
<td>Direct gene expression measurement in skin helps predict long-term clinical outcome in patients with cutaneous T-cell lymphomas</td>
<td>Adele de Masson</td>
<td>10:35-12:00</td>
</tr>
<tr>
<td>G-03</td>
<td>Development of an in vitro CTCL platform for screening targeted molecular agents</td>
<td>Jason Weed</td>
<td>10:35-12:00</td>
</tr>
<tr>
<td>G-04</td>
<td>High-throughput T cell receptor sequencing transforms care of cutaneous T cell lymphoma patients</td>
<td>John O’Malley</td>
<td>10:35-12:00</td>
</tr>
<tr>
<td>G-05</td>
<td>TCR sequencing facilitates diagnosis and identifies mature T cells as the cell of origin in cutaneous T-cell lymphoma</td>
<td>Lanny Kirsch</td>
<td>10:35-12:00</td>
</tr>
<tr>
<td>G-06</td>
<td>Integrative analysis of genomic data to identify common genomic alterations in cutaneous T-cell lymphoma</td>
<td>Li-Wei Chang</td>
<td>10:35-12:00</td>
</tr>
<tr>
<td>G-07</td>
<td>Genomic landscape of Mycosis fungoides</td>
<td>Jinah Yoo</td>
<td>10:35-12:00</td>
</tr>
<tr>
<td>G-08</td>
<td>Lessons Learned From a Novel Mouse Model of CTCL</td>
<td>Sergei B. Koralov</td>
<td>10:35-12:00</td>
</tr>
</tbody>
</table>

**Scientific Session H. Cutaneous B-cell lymphomas**

**Chairs:** Hodak, Junkins-Hopkins, Guitart

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Presenter</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>H-01</td>
<td>Immunoglobulin constant region mutations in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type</td>
<td>Marvyn T. Koning</td>
<td>13:30-14:25</td>
</tr>
<tr>
<td>H-02</td>
<td>The B-Cell Receptor of Primary Cutaneous Follicle Center Lymphoma: Implications for Pathogenesis</td>
<td>Marvyn T. Koning</td>
<td>13:30-14:25</td>
</tr>
</tbody>
</table>
H-03 PD1 and PD-L1 expression in primary cutaneous diffuse large B cell lymphoma
Christina Mitteldorf 9

H-04 Primary cutaneous diffuse large B-cell lymphoma, leg-type: high frequency, diagnostic and prognostic value of MYD88 L265P mutation
Anne Pham-Ledard 9

H-05 Primary Cutaneous B-Cell Lymphoma – Systemic spread is rare whilst cutaneous relapses and secondary malignancies are frequent
Sue Ann Chan 9

14:25-14:45 Break & Poster Viewing

14:45-15:50 Scientific Session I. Rare Cutaneous Lymphomas
Chairs: Berti, Cerroni, Rosen, Kadin

I-01 Introduction + A new look at atopy in CD30+ Cutaneous Lymphoproliferative Disorders
Marshall Kadin 15

I-02 TOX expression in cutaneous T-cell lymphomas and cutaneous B-cell lymphomas
Anne M.R. Schrader 7

I-03 No TP63 rearrangements in a selected group of primary cutaneous CD30+ lymphoproliferative disorders with aggressive clinical course
Anne M.R. Schrader 7

I-04 Skin manifestations and outcome in adults with pre-B cell acute lymphoblastic leukemia; an important differential diagnosis to primary cutaneous follicle center lymphoma, diffuse type and secondary cutaneous follicular lymphoma
Yann Charli Joseph 9

Charlotte Hurabielle 9

I-06 Blastic Plasmacytoid Dendritic Cell Neoplasm: an update on cytogenetic data
Emilio Berti 9

Nicolas Ortonne 9

15:50-16:00 Break

16:00-17:00 Scientific Session J. Quality of Life & Outcomes Studies [Concurrent Session]
Chairs: McCann, Tawa, Finnegan, Zic

J-01 Cost-Effectiveness Analysis of Systemic Treatments for Cutaneous T-Cell Lymphoma
Larisa Geskin 9

J-02 Development and validation of the first measure of quality of life specific for patients with Mycosis Fungoides/Sézary syndrome
Stacey McCaffrey 9

J-03 Large prospective observational registry in MF-CTCL
Badri Rengarajan 9

J-04 Assessment of QOL, illness perception, and illness behavior in 92 patients with primary cutaneous lymphoma
Stefanie Porkert 9

J-05 Caregiver Burden and Qulaity of Life Factors Affecting Caregivers of Patients with Cutaneous T-Cell Lymphoma
Sue A. McCann 9

16:00-17:00 Scientific Session K. Clinical Aspects [Concurrent Session]
Chairs: Pinter-Brown, Pittelkow, Sanches, Myskowski

K-01 Cutaneous lymphomas during anti-tumor necrosis factor therapy are often associated with misdiagnosed “psoriasis” or poorly characterized “dermatitis”
Estela Martinez-Escala 9

K-02 Poor Outcome of Patients with Transformed Mycosis Fungoides: Analysis from a Prospective Multicenter US Cohort Study
Frederick Lansigan 9

K-03 Sézary syndrome without erythroderma
Liliane Laroche 9

K-04 Risk of venous thromboembolism in patients with parapsoriasis (early mycosis fungoides): A Danish nationwide population-based cohort study
Lise M. Lindahl 9

K-05 Protean Manifestations of Early Sézary Syndrome
Robert Gniadecki 9

16:00-17:00 Scientific Session L. Applied Research [Concurrent Session]
Chairs: Schieke, Hwang, Korakov, Gniadecki

L-01 Introduction + An in vitro model of psoralen ultraviolet A (PUVA)-induced apoptosis of cutaneous lymphoma cell lines: Augmentation by type I interferons via JAK1-STAT1 pathway
Robert Gniadecki 15

L-02 MYD88 mutations in a distinct type of cutaneous marginal zone lymphoma with a non-class switched IgM-immunophenotype
Marion Wobser 9

L-03 Analysis of the expression and activity of metalloproteinases 2 and 9 and their inhibitors and correlation with histological findings and prognosis in mycosis fungoides
Roberta Vasconcelos 9

L-04 Impact of immunodeficiency on outcomes and immune-checkpoint molecule expression in mycosis fungoides
Melissa Pultitzer 9

L-05 Role of PAK1 in the onset and progression of cutaneous T-cell lymphoma
Yimeng Wang 9

L-06 Doxycycline is an NF-kB Inhibitor That Induces Apoptotic Cell Death in Malignant T-cells
Brian Poligone 9

17:15-18:15 Shuttle to Dinner Cruise

18:15-21:30 Congress Dinner Cruise
FRIDAY, October 28, 2016

07:00-08:00  USCLC Board of Directors Meeting
08:00-10:30  Scientific Session M. Therapeutics 1a: Translational/Pre-clinical Studies
             Chairs: Zain, Papadavid, Prince, Bates

◊ Introduction + CTCL as a disease of epigenetic dysregulation
M-01 Novel treatment option for CTCL: Studying the effects of dimethylfumarate from bench to bedside
M-02 Translational Development of MRG-106, an Oligonucleotide Inhibitor of miR-155, as a Novel Therapy for CTCL
M-03 Chimeric Antigen Receptor Modified T cells Targeting Chemokine Receptor CCR4 as a Therapeutic Modality for T-cell Malignancies including CTCL
M-04 Differential transcriptome response in mycosis fungoides patients following silicon phthalocyanine 4 photodynamic therapy
M-05 Preclinical Investigation of SGN-CD70A Drug-Antibody Conjugate in T Cell Lymphomas
M-06 Characterization of CD70 immunoperoxidase staining on cutaneous T-cell lymphomas

09:10-09:20  Quick Break and switch Chairs
09:20-10:30  Scientific Session M. Therapeutics 1b: Translational/Pre-clinical Studies
             Chairs: Whittaker, Dummer, Pimpinelli, Bates

M-07 Synergy of romidepsin and mechlorethamine in cutaneous T-cell lymphoma
M-08 RARa/RXR Synergism Potentiates Responsiveness in Cutaneous T Cell Lymphoma
M-09 AN-7 sensitizes cutaneous T-cell lymphoma cell lines to doxorubicin via inhibition of double-strand break repair
M-10 Resminostat - an epigenetic approach for CTCL maintenance treatment
M-11 Apoptosis induction in Cutaneous T-cell Lymphoma Cells after Treatment with Lenalidomide
M-12 PI3K-gamma use in CTCL

10:30-10:45  Break & Poster Viewing
10:45-11:45  Scientific Session N. Therapeutics 2: Advanced Therapies, including HSC Transplantation
             Chairs: Horowitz, Foss, Hoppe, Weng, Porcu

N-01 Long-term outcome of allogeneic hematopoietic stem cell transplantation for patients with mycosis fungoides and Sézary syndrome
N-02 Allogeneic Stem Cell Transplantation in Refractory MF/SS: Results with Reduced Intensity Conditioning Regimen
N-03 Pralatrexate in Cutaneous T cell Lymphoma: Retrospective Experience with and without Leucovorin
N-04 Low dose Total Skin Electron Beam therapy (TSEB) 12Gy in 8 # over 2 weeks. The results in 103 patients from the UK.
N-05 The French Experience of Chlormethine Gel for the Treatment of Mycosis Fungoides:A Retrospective Series of 107 cases

11:45-12:00  ISCL General Meeting
12:00-13:00  Lunch & Poster Viewing
12:00-13:30  CME SYMPOSIUM: Immunology & Immunotherapy of Cutaneous Lymphomas
             Animal Models as a Means to Study the Tumor Microenvironment in CTCL
             Pathogenesis of Immune Compromise in the CTCL Patient
             Importance of the Innate Immune Response in Therapy of CTCL
             New Immunotherapies in Clinical Development
             Chairs: Bagot, Kim, Y, Lebwohl, Horwitz

13:30-15:35  Scientific Session O. Therapeutics 3a: Endpoints & Clinical Trials
             Chairs: Bagot, Kim, Y, Lebwohl, Horwitz

◊ Introduction + Landscape of new therapeutics in CL
O-01 Exploring New Meaningful Endpoints for CTCL Clinical Trials in Two Phase II Studies of Brentuximab Vedotin (BV) in Patients with Mycosis Fungoides (MF) and Sézary Syndrome (SS)
O-02 KIR3DL2 expression in cutaneous T-cell lymphomas: a widely-shared target
O-03 First-in-Human, open label, multicenter phase 1 study of IPH4102, first-in-class humanized anti-KIR3DL2 mAb, in relapsed/refractory CTCL: preliminary safety and clinical activity results
O-04 E7777 Demonstrated Safety in Persistent or Recurrent Cutaneous T-Cell Lymphoma
O-05 A Single-arm Phase 2A Study of NM-IL-12 (rHu-IL12) in Patients with Mycosis Fungoides-Type CTCL (MF) Undergoing Low-Dose Total Skin Electron Beam Therapy (LD-TSEBT)
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Session/Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:30-15:35</td>
<td>Quick Break and switch Chairs</td>
<td>Scientific Session O. Therapeutics 3b: Endpoints &amp; Clinical Trials</td>
</tr>
<tr>
<td></td>
<td><strong>Chairs:</strong> Duvic, Akilov, Sawas, Feldman</td>
<td></td>
</tr>
<tr>
<td>O-06</td>
<td>Lenalidomide in relapsed or refractory primary cutaneous large B-cell lymphomas, leg-type: first results of a multicentric prospective phase II trial &quot;REV-LEG&quot;</td>
<td>Marie Beylot-Barry 10</td>
</tr>
<tr>
<td>O-07</td>
<td>Phase 1, Single-Arm, Open-Label, Dose Escalation Trial of Microneedle Array-Doxorubicin in Patients with Cutaneous T cell Lymphoma</td>
<td>Oleg Akilov 10</td>
</tr>
<tr>
<td>O-08</td>
<td>Interim analysis of phase II clinical trial PimToMF (Topical Pimecrolimus in early MF) Eudra CT 2014-001377-14</td>
<td>Pablo L. Ortiz Romero 10</td>
</tr>
<tr>
<td>O-09</td>
<td>Preliminary results of Phase I, anti-CD37-MMAE conjugate in CTCL (LATE BREAKING)</td>
<td>Ahmed Sawas 10</td>
</tr>
<tr>
<td>O-10</td>
<td>Potentials: CITN-10 pembrolizumab in MF/SS (LATE BREAKING)</td>
<td></td>
</tr>
<tr>
<td>15:35-15:50</td>
<td>Break &amp; Poster Viewing</td>
<td></td>
</tr>
<tr>
<td>15:50-16:50</td>
<td>Scientific Session P: Clinical Management and Challenging Cases</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Chairs:</strong> Kim, E, Hymes, Latkowski, Heald</td>
<td></td>
</tr>
<tr>
<td>P-01</td>
<td>The Effect of Phototherapy on Progression to Tumors in Patients with Patch-Plaque Stage Mycosis Fungoides</td>
<td>Joyce W. Hoot 8</td>
</tr>
<tr>
<td>P-02</td>
<td>Total Skin Electron Beam (TSEB) therapy for the management of T cell cutaneous lymphomas. The evolving role of low dose (12 Gy) treatment schedule</td>
<td>John Georgakopoulos 8</td>
</tr>
<tr>
<td>P-03</td>
<td>Eyelid involvement by MF/CTCL: a management challenge</td>
<td>Ellen J. Kim 8</td>
</tr>
<tr>
<td>P-04</td>
<td>The French Experience of Treatment of Cutaneous T Cell Lymphoma with Brentuximab Vedotin: A series of 32 Cases</td>
<td>Steve Mathieu 8</td>
</tr>
<tr>
<td>P-05</td>
<td>Evaluation of treatment in indolent and aggressive subgroups of folliculotropic mycosis fungoides</td>
<td>Suzanne van Santen 8</td>
</tr>
<tr>
<td>P-06</td>
<td>Treatment of early-stage folliculotropic mycosis fungoides: A single-center experience</td>
<td>Iris Amitay-Laish 8</td>
</tr>
<tr>
<td>16:50-17:00</td>
<td>Congress Conclusion &amp; Closing Remarks</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Authors:</strong> Martin Vermeer &amp; Larisa Geskin</td>
<td></td>
</tr>
</tbody>
</table>